Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...

In a 2024 review, Richardson and colleagues noted that the immunomodulatory drugs thalidomide, lenalidomide (Revlimid), and ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

Of the 3M SF of lab space construction in progress in the metro area, more than half is either build-to-suit in or has some ...

And GSK announced Thursday that the FDA had approved its medication gepotidacin, with the brand name Blujepa, as oral tablets ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK and UK-based rival AstraZeneca have revealed billions of dollars in US investment in recent months in response to ...

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ...

hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...